Operating Income (Loss) in USD of Larimar Therapeutics, Inc. from 2012 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Larimar Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and change rate from 2012 to Q3 2025.
  • Larimar Therapeutics, Inc. Operating Income (Loss) for the quarter ending 30 Sep 2025 was -$49.5M, a 171% decline year-over-year.
  • Larimar Therapeutics, Inc. Operating Income (Loss) for the twelve months ending 30 Sep 2025 was -$140M, a 89.5% decline year-over-year.
  • Larimar Therapeutics, Inc. annual Operating Income (Loss) for 2024 was -$90.9M, a 118% decline from 2023.
  • Larimar Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$41.8M, a 14.3% decline from 2022.
  • Larimar Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$36.5M, a 27.6% increase from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

Larimar Therapeutics, Inc. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$140M -$49.5M -$31.2M -171% 01 Jul 2025 30 Sep 2025 10-Q 05 Nov 2025
Q2 2025 -$109M -$27.8M -$3.19M -13% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025
Q1 2025 -$105M -$31.2M -$14.5M -86.4% 01 Jan 2025 31 Mar 2025 10-Q 30 Apr 2025
Q4 2024 -$90.9M -$31.3M -$17.1M -121% 01 Oct 2024 31 Dec 2024 10-K 24 Mar 2025
Q3 2024 -$73.8M -$18.3M -$7.93M -76.7% 01 Jul 2024 30 Sep 2024 10-Q 05 Nov 2025
Q2 2024 -$65.8M -$24.6M -$15M -156% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025
Q1 2024 -$50.9M -$16.7M -$9.1M -119% 01 Jan 2024 31 Mar 2024 10-Q 30 Apr 2025
Q4 2023 -$41.8M -$14.2M -$3.72M -35.7% 01 Oct 2023 31 Dec 2023 10-K 24 Mar 2025
Q3 2023 -$38M -$10.3M -$1.83M -21.5% 01 Jul 2023 30 Sep 2023 10-Q 30 Oct 2024
Q2 2023 -$36.2M -$9.62M -$933K -10.7% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024
Q1 2023 -$35.3M -$7.64M +$1.25M +14.1% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024
Q4 2022 -$36.5M -$10.4M -$1.35M -14.9% 01 Oct 2022 31 Dec 2022 10-K 14 Mar 2024
Q3 2022 -$35.2M -$8.51M +$8.22M +49.1% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023
Q2 2022 -$43.4M -$8.69M +$3.86M +30.7% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023
Q1 2022 -$47.2M -$8.89M +$3.22M +26.6% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023
Q4 2021 -$50.5M -$9.09M +$5.31M +36.9% 01 Oct 2021 31 Dec 2021 10-K 14 Mar 2023
Q3 2021 -$55.8M -$16.7M -$6.4M -61.9% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022
Q2 2021 -$49.4M -$12.5M -$1.14M -10% 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022
Q1 2021 -$48.2M -$12.1M -$5.43M -81.4% 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022
Q4 2020 -$42.8M -$14.4M -$16.8M -701% 01 Oct 2020 31 Dec 2020 10-K 25 Mar 2022
Q3 2020 -$26M -$10.3M -$1.71M -19.8% 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021
Q2 2020 -$24.3M -$11.4M -$7.7M -208% 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021
Q1 2020 -$16.6M -$6.67M +$6.6M +49.7% 01 Jan 2020 31 Mar 2020 10-Q 10 May 2021
Q4 2019 -$23.2M $2.4M +$17.1M 01 Oct 2019 31 Dec 2019 10-K 04 Mar 2021
Q3 2019 -$40.3M -$8.63M +$6.54M +43.1% 01 Jul 2019 30 Sep 2019 10-Q 12 Nov 2020
Q2 2019 -$46.8M -$3.7M +$11.9M +76.2% 01 Apr 2019 30 Jun 2019 10-Q 14 Aug 2020
Q1 2019 -$58.7M -$13.3M +$2.43M +15.4% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020
Q4 2018 -$61.1M -$14.7M -$1.33M -9.98% 01 Oct 2018 31 Dec 2018 10-K 05 Mar 2020
Q3 2018 -$59.8M -$15.2M -$2.33M -18.1% 01 Jul 2018 30 Sep 2018 10-Q 06 Nov 2019
Q2 2018 -$57.5M -$15.6M -$2.02M -15% 01 Apr 2018 30 Jun 2018 10-Q 08 Aug 2019
Q1 2018 -$55.4M -$15.7M -$2.44M -18.4% 01 Jan 2018 31 Mar 2018 10-Q 09 May 2019
Q4 2017 -$53M -$13.4M -$2.88M -27.5% 01 Oct 2017 31 Dec 2017 10-K 05 Mar 2020
Q3 2017 -$50.1M -$12.8M +$1.99M +13.4% 01 Jul 2017 30 Sep 2017 10-Q 09 Nov 2018
Q2 2017 -$52.1M -$13.5M +$1.53M +10.1% 01 Apr 2017 30 Jun 2017 10-Q 09 Aug 2018
Q1 2017 -$53.6M -$13.3M +$4.59M +25.7% 01 Jan 2017 31 Mar 2017 10-Q 09 May 2017
Q4 2016 -$58.2M -$10.5M +$12.8M +54.9% 01 Oct 2016 31 Dec 2016 10-K 14 Mar 2019
Q3 2016 -$71M -$14.8M +$4.89M +24.8% 01 Jul 2016 30 Sep 2016 10-Q 07 Nov 2017
Q2 2016 -$75.9M -$15.1M +$2.55M +14.5% 01 Apr 2016 30 Jun 2016 10-Q 09 Aug 2017
Q1 2016 -$78.4M -$17.9M -$4.62M -34.9% 01 Jan 2016 31 Mar 2016 10-Q 09 May 2017
Q4 2015 -$73.8M -$23.2M -$12.6M -118% 01 Oct 2015 31 Dec 2015 10-K 09 Mar 2018
Q3 2015 -$61.2M -$19.7M -$5.36M -37.3% 01 Jul 2015 30 Sep 2015 10-Q 09 Nov 2016
Q2 2015 -$55.9M -$17.6M -$11.6M -194% 01 Apr 2015 30 Jun 2015 10-Q 05 Aug 2016
Q1 2015 -$44.3M -$13.2M -$8.72M -193% 01 Jan 2015 31 Mar 2015 10-Q 10 May 2016
Q4 2014 -$35.5M -$10.7M 01 Oct 2014 31 Dec 2014 10-K 10 Mar 2017
Q3 2014 -$14.4M -$10.8M -308% 01 Jul 2014 30 Sep 2014 10-Q 13 Nov 2015
Q2 2014 -$5.99M -$3.01M -101% 01 Apr 2014 30 Jun 2014 10-Q 14 Aug 2015
Q1 2014 -$4.52M 01 Jan 2014 31 Mar 2014 10-Q 14 May 2015
Q3 2013 -$3.52M 01 Jul 2013 30 Sep 2013 10-Q 13 Nov 2014
Q2 2013 -$2.98M 01 Apr 2013 30 Jun 2013 10-Q 14 Aug 2014

Larimar Therapeutics, Inc. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$90.9M -$49.1M -118% 01 Jan 2024 31 Dec 2024 10-K 24 Mar 2025
2023 -$41.8M -$5.23M -14.3% 01 Jan 2023 31 Dec 2023 10-K 24 Mar 2025
2022 -$36.5M +$13.9M +27.6% 01 Jan 2022 31 Dec 2022 10-K 14 Mar 2024
2021 -$50.5M -$7.66M -17.9% 01 Jan 2021 31 Dec 2021 10-K 14 Mar 2023
2020 -$42.8M -$19.6M -84.4% 01 Jan 2020 31 Dec 2020 10-K 25 Mar 2022
2019 -$23.2M +$37.9M +62% 01 Jan 2019 31 Dec 2019 10-K 04 Mar 2021
2018 -$61.1M -$8.12M -15.3% 01 Jan 2018 31 Dec 2018 10-K 05 Mar 2020
2017 -$53M +$5.23M +8.98% 01 Jan 2017 31 Dec 2017 10-K 05 Mar 2020
2016 -$58.2M +$15.6M +21.1% 01 Jan 2016 31 Dec 2016 10-K 14 Mar 2019
2015 -$73.8M -$38.3M -108% 01 Jan 2015 31 Dec 2015 10-K 09 Mar 2018
2014 -$35.5M -$21.8M -158% 01 Jan 2014 31 Dec 2014 10-K 10 Mar 2017
2013 -$13.8M +$11K +0.08% 01 Jan 2013 31 Dec 2013 10-K 15 Mar 2016
2012 -$13.8M 01 Jan 2012 31 Dec 2012 10-K 25 Mar 2015
* An asterisk sign (*) next to the value indicates that the value is likely invalid.